The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma

Filip Janku, MD, PhD
Published Online: 4:58 PM, Mon June 2, 2014
Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma. Researchers concluded that this combination of agents was well tolerated and demonstrated encouraging activity.

<<< Back to the ASCO 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.